German industry opposes BfArM role in medtech clinical trials approvals
This article was originally published in Clinica
German medical device companies are coming out in opposition to a provision in the draft medical device law revision (MPG4) that requests companies conducting clinical trials to obtain approval for device trials from the competent authority.
You may also be interested in...
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.